Clinical trials
Nasopharyngeal Carcinoma (NPC) clinical trials
Below are recruiting nasopharyngeal carcinoma (npc) clinical trials, each written for real people, not researchers. We’re tracking 90 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07232680Recruiting
Immune profile study for nasopharyngeal cancer patients
This study looks at how the immune system responds to radiation therapy for nasopharyngeal cancer. It will use scans and blood tests to find markers that might predict how well treatment works.
Taoyuan City, TaiwanAges 18 years+ - NCT06886347RecruitingPhase 1
New treatment for metastatic nasopharyngeal cancer before chemotherapy
This trial tests a new treatment for people with advanced nasopharyngeal cancer that has spread (stage IVb) and who have not yet had chemotherapy. It aims to see if the experimental treatment is safe and effective as a first option.
Hangzhou, ZhejiangAges 18–75 - NCT03907826RecruitingPhase 3
PD-1 therapy plus chemoradiation for recurrent nasopharyngeal cancer
This trial studies whether adding a PD-1 antibody (an immunotherapy) to standard chemoradiation can better control recurrent nasopharyngeal cancer that can’t be removed with surgery. If you qualify, you’d receive the study treatment and be closely monitored for side effects and cancer response.
Guangzhou, GuangdongAges 18–70 - NCT06976190RecruitingPhase 3
MRG003 plus pucotenlimab vs chemo for advanced nasopharyngeal cancer
This trial tests whether combining an experimental antibody-drug conjugate (MRG003) with an immunotherapy (pucotenlimab) works better than standard chemotherapy for people with nasopharyngeal cancer that has come back or spread. If you have tried at least one prior treatment and are generally in good health, you may be able to join.
Guangzhou, GuangdongAges 18–75 - NCT06676722RecruitingPhase 2
SBRT and two targeted drugs for advanced nasopharyngeal cancer
This trial tests a combination of focused radiation (SBRT) and two targeted drugs (nimotuzumab and tislelizumab) for people with nasopharyngeal cancer that has come back or spread to a few spots (1-5) after prior immunotherapy. It aims to see if this triple therapy can help control the disease when standard treatment has stopped working.
Xiamen, FujianAges 18–75 - NCT06282497Recruiting
New radiation technique to reduce dry mouth in nasopharyngeal cancer
This trial compares a new radiation technique designed to reduce dry mouth (xerostomia) with standard radiation for people with nasopharyngeal cancer. It aims to see if the new approach can protect saliva glands while still treating the cancer effectively.
Zhongshan, GuangdongAges 18–70 - NCT04830267RecruitingPhase 2
Camrelizumab plus focused radiation for recurrent metastatic nasopharyngeal cancer
This Phase 2 trial studies whether adding camrelizumab (an immune medicine) to stereotactic body radiation (focused, high-precision radiation) helps people with recurrent or metastatic nasopharyngeal cancer. It aims to improve control of the cancer (and may use blood EBV levels to help track response).
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT05514275RecruitingPhase 2
Radiation plus endostatin and capecitabine for nasopharyngeal cancer
This Phase 2 trial tests whether adding endostatin and capecitabine to standard radiation can improve outcomes for people with non-keratinizing nasopharyngeal cancer that has not responded well to chemotherapy. It may help those with stable or worsening disease after treatment before moving to radiation.
Hangzhou, ZhejiangAges 18–65 - NCT05854849RecruitingPhase 3
Testing three-drug therapy versus cisplatin for recurrent NPC
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
Guangzhou, GuangdongAges 18–75 - NCT06026878RecruitingPhase 3
GNT induction treatment for advanced nasopharyngeal cancer
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
Xi'an, ShaanxiAges 18–75 - NCT06059261RecruitingPhase 2
Envafolimab plus chemoradiation and endostatin for advanced nasopharyngeal cancer
This trial tests a combination of a new immunotherapy (envafolimab) with standard chemoradiation and a drug that blocks blood vessel growth (endostatin) for people with advanced nasopharyngeal cancer that hasn't been treated before. The goal is to see if this combination works better than the usual treatment.
Chongqing, Chongqing MunicipalityAges 18–65 - NCT06177301RecruitingPhase 3
Comparing two drug combos for recurrent nasopharyngeal cancer
This study compares two combinations of drugs (tislelizumab plus either GX or GP) to see which works better for people with nasopharyngeal cancer that has returned or spread and has not been treated with systemic therapy before.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06182657Recruiting
Nasopharyngeal cancer response to induction chemotherapy
This study looks at how well nasopharyngeal cancer (NPC) responds to the first round of chemotherapy before other treatments. It aims to see if the amount of tumor shrinkage can help predict outcomes and guide future care for people with advanced NPC.
Nanchang, JiangxiAges 18 years+ - NCT06752239RecruitingPhase 3
Optimizing radiation to protect thyroid in nasopharyngeal cancer
This trial tests a way to adjust radiation therapy to better protect the thyroid gland during treatment for nasopharyngeal carcinoma. It aims to reduce thyroid damage while still effectively treating the cancer.
Nanchang, JiangxiAges 18–70 - NCT07376603Recruiting
Radiation therapy alone for early-stage nasopharyngeal cancer
This trial tests whether intense radiation therapy (IMRT) alone is effective for people with stage IB nasopharyngeal carcinoma (a type of head and neck cancer) that has not spread to lower lymph nodes or formed large, matted nodes. If you qualify, you would receive targeted radiation without chemotherapy.
Fuzhou, FujianAges 18–70 - NCT05652192RecruitingPhase 2
SBRT radiation plus chemotherapy and immunotherapy for metastatic nasopharyngeal cancer
This trial tests whether adding targeted radiation (SBRT) to chemotherapy and an immunotherapy drug can help people with metastatic nasopharyngeal cancer live longer and control tumors. It may help by combining local tumor treatment with whole-body immune support.
Hangzhou, ZhejiangAges 18–75 - NCT06228079RecruitingPhase 3
Chemo-immunotherapy after surgery for early reoccurring nasopharyngeal cancer
This study looks at whether adding chemo-immunotherapy after surgery is better than surgery alone for patients whose nasopharyngeal cancer has returned but is still in early stages. It may help prevent the cancer from coming back again.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06235203RecruitingPhase 3
Comparing treatment timing in recurrent nasopharyngeal cancer
This trial compares giving chemotherapy and immunotherapy before surgery (neoadjuvant) versus after surgery (adjuvant) for patients whose nasopharyngeal cancer has returned locally. It aims to find which approach works better to control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06241612RecruitingPhase 3
Personalized neck radiation for nasopharyngeal cancer
This trial tests whether giving radiation only to the specific lymph nodes that need it works as well as standard radiation for people with nasopharyngeal cancer. It aims to reduce side effects while still controlling the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06389201Recruiting
Hydroxychloroquine before radiation and chemo for NPC
This trial tests whether taking hydroxychloroquine (HCQ) before standard radiation and chemo can help treat advanced nasopharyngeal cancer. It is for patients who have not yet started any cancer therapy.
Nantong, JiangsuAges 20–70 - NCT06733948RecruitingPhase 2
Dental stent to protect taste during NPC radiation
This trial tests whether a custom-fitted dental stent (like a mouthguard) can help protect your sense of taste during radiation and chemotherapy for nasopharyngeal cancer. If you qualify, you'll receive either standard care or the stent, and your taste changes will be tracked.
SingaporeAges 21–100 - NCT05892354Recruiting
Immunonutrition to reduce mouth sores after cancer treatment
This trial studies whether special nutritional supplements (immunonutrients) can reduce painful mouth sores (oral mucositis) in people with nasopharyngeal cancer after chemoradiotherapy. If you qualify, you’ll be followed with visits and lab tests to see if the supplements improve comfort and recovery.
Fuzhou, FujianAges 18–70 - NCT06831357Recruiting
Predicting Cancer Spread in Nasopharyngeal Cancer Using AI
This trial uses a deep learning computer model to look at tissue images and MRI scans to predict whether nasopharyngeal carcinoma may spread to other parts of the body. It may help doctors decide on the best treatment for people with certain stages of this cancer.
Guangzhou, GuangdongAges Any age - NCT07067268RecruitingPhase 2
Tislelizumab and capecitabine for nasopharyngeal cancer with remaining EBV DNA
This trial tests a combination of two drugs, tislelizumab and capecitabine, for people with nasopharyngeal cancer who still have detectable EBV DNA in their blood after finishing radiation therapy. The goal is to see if this treatment can help clear the virus and improve outcomes.
Shanghai, ChinaAges 18 years+
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nasopharyngeal carcinoma (npc)?
- Yes. Clin2 currently lists 90 recruiting nasopharyngeal carcinoma (npc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nasopharyngeal carcinoma (npc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nasopharyngeal carcinoma (npc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.